Strs Ohio Takes Position in Theravance Biopharma, Inc. $TBPH

Strs Ohio acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 44,100 shares of the biopharmaceutical company’s stock, valued at approximately $644,000. Strs Ohio owned about 0.09% of Theravance Biopharma at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the last quarter. State of Wyoming lifted its position in shares of Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares during the period. Campbell & CO Investment Adviser LLC increased its holdings in shares of Theravance Biopharma by 4.4% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 52,617 shares of the biopharmaceutical company’s stock worth $768,000 after acquiring an additional 2,225 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Theravance Biopharma by 12.4% in the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,789 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TBPH shares. HC Wainwright lifted their price objective on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective for the company. Finally, BTIG Research upped their target price on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.80.

Theravance Biopharma Stock Up 0.8%

NASDAQ TBPH opened at $19.18 on Friday. The company has a market capitalization of $971.85 million, a P/E ratio of 33.65 and a beta of 0.14. Theravance Biopharma, Inc. has a 12-month low of $7.90 and a 12-month high of $21.03. The firm has a 50-day moving average price of $19.01 and a two-hundred day moving average price of $15.58.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.10. The company had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. Equities analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.